Transcatheter aortic valve replacement (TAVR) and minimally invasive aortic valve replacement (miniAVR) have become alternatives to surgical aortic valve replacement via median sternotomy (SAVR) to treat severe aortic stenosis (AS). Despite increased interest and utilization, few studies have directly compared TAVR and miniAVR. A review of the current literature shows TAVR to be an indispensable tool for inoperable, high-risk, and perhaps intermediate-risk patients with severe AS. However, it is associated with a number of deleterious perioperative outcomes, such as valvular regurgitation and vascular complications. MiniAVR is associated with decreased intensive care unit (ICU) and hospital length of stay, a lower incidence of blood transfusions, decreased ventilation time, and improved cosmetic results. MiniAVR maintains potential advantages over SAVR, including the implantation of a durable prosthesis and low rates of perioperative myocardial infarction and paravalvular leak. It is associated with longer aortic cross clamp and cardiopulmonary bypass (CPB) times; however, the use of sutureless valve implants can circumvent this. Studies comparing TAVR and miniAVR demonstrate decreased postoperative mortality, valvular regurgitation, and incidence of stroke in the miniAVR cohorts. Few studies currently exist comparing TAVR and miniAVR, as it is hard to compare the typically low-risk miniAVR versus high-risk TAVR patient populations. It is clear that both strategies will be cornerstones in the modern AVR era, but the situations in which to apply each strategy have not yet been clearly delineated. This highlights the need for surgeons to adopt these minimally invasive techniques. We believe there is a compelling role for miniAVR in low-and intermediate-risk patients, but due to the paucity of data, neither TAVR nor miniAVR should be discounted before a randomized, risk-stratified trial is performed. More studies are needed to compare TAVR and miniAVR in low-and intermediate-risk patients.
Introduction
Aortic valve replacement (AVR) is the second most common cardiac procedure performed, with aortic stenosis (AS) being the most common valve disease as a result of an aging population (1) . A prospective, population-based study found the incidence of AS to be 0.2% in the 50-59 years cohort, 1.3% in the 60-69 years cohort, 3.9% in the 70-79 years cohort, and 9.8% in the 80-89 years cohort (2) .
A survival rate of 50% at 2 years and 20% at 5 years after symptom onset has prompted the development of multiple therapeutic strategies (3) .
Traditionally, surgical aortic valve replacement via median sternotomy (SAVR) has been the gold standard to treat severe AS, as this approach has been highly successful in providing freedom from structural valve failure rates of 70-90% at 10 years and 50-80% at 15 years (4). However, in this era of advancements in minimally invasive operations, patients increasingly want the least invasive approach to correct complex problems, assuming that it is safe, as good as the status quo, and potentially cost effective. In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a promising option for high-and potentially intermediate-risk patients, and there are several studies comparing TAVR versus SAVR. The drive towards minimally invasive strategies has also increased the demand and adoption of minimally invasive aortic valve replacement (miniAVR). Nguyen et al. demonstrated an increased growth for both of these techniques between 2011 and 2014 (5). Transfemoral TAVR and miniAVR displayed a 595% and 57% increase from 2011 to 2014, respectively (5). Johnston and Roselli reported an increase in miniAVR from 12.4% to 29.6% of the total aortic valve procedures at the Cleveland Clinic, from 1996 to 2013 (6) .
Despite the increased interest in TAVR and miniAVR, only a handful of studies comparing both approaches exist. The goal of this article is to provide an in-depth review of the current literature comparing TAVR and miniAVR for patients with severe AS.
Results

TAVR
One of the major advancements in the management of severe AS came with the introduction of TAVR in 2002. Before this intervention, at least 30% of patients with severe, symptomatic AS did not undergo SAVR due to comorbidities and risk (7) 
MiniAVR
A second option for minimally invasive AVR is miniAVR. This is typically performed via right anterior thoracotomy or ministernotomy in lieu of a full median sternotomy. This reduces the incision from an average of 24.5 to 7.17 cm with a ministernotomy, or a 5 cm incision with a thoracotomy (13, 14) . MiniAVR has been shown to: reduce length of intensive care unit (ICU) and hospital stay, reduce ventilation time, decrease the need for blood transfusion, decrease pain, and improve the cosmetic result (15) (16) (17) . A Cochrane review that included seven randomized controlled trials compared AVR via median sternotomy vs. were comparable between the minithoracotomy and ministernotomy groups, respectively (20) .
TAVR vs. miniAVR
Few studies have directly compared TAVR and miniAVR. Miceli et al. retrospectively analyzed patients with severe AS who underwent either TAVR, via transapical or transfemoral approach, or miniAVR via a right thoracotomy with a sutureless valve. After propensity score analysis, 37 matched pairs were compared. The in-hospital mortality rate was 8.1% in the TAVR group and 0% in the miniAVR group (P=0.25) (21). Rates of stroke and transient ischemic attack were 5.4% and 2.7% (P=0.3) in the TAVR group, respective to the approaches noted above, with none occurring in the miniAVR group at a median followup period of 13 months (21). Although not statistically significant, the survival rates were higher in the miniAVR cohort compared to TAVR (91.6% vs. 78.6% at 1 year and 91.6% vs. 66.2% at 2 years, respectively (HR =0.7; 95% CI, 0.7 to 49.8; P=0.1)) (21) . The TAVR cohort demonstrated higher rates of mild and moderate paravalvular leak (37.8% and 27%, respectively) compared to the miniAVR cohort (2.7% mild and 0% moderate) (P<0.001) (21).
Santarpino et al. reported similar results with a retrospective, propensity score analysis comparing TAVR vs. miniAVR with a sutureless valve in high-risk patients. They report an incidence of aortic regurgitation of 13.5% in the TAVR group vs. 0% in the miniAVR group (P=0.27) and a cumulative survival of 86.5% vs. 97.3% (P=0.015) in the TAVR and miniAVR cohorts respectively, with a mean follow-up of 18.9 months (22).
Terwelp et al. performed a propensity score analysis comparing SAVR, TAVR and miniAVR (23) . Analysis of the matched transfemoral TAVR and miniAVR pairs demonstrated no difference in 30-day mortality. Transfemoral TAVR was associated with a higher postoperative stroke rate compared to miniAVR (3.6% vs. 0.4%; P=0.02), but a lower incidence of postoperative atrial fibrillation (4% vs. 19.4%; P<0.01) (23) .
Discussion
The emergence of TAVR has offered a means to treat inoperable patients with severe AS, with its use quickly expanding to high-risk patients and future applications in sight for intermediate-and low-risk patients. The ability to replace the aortic valve via a small groin incision is a highly attractive option to patients, compared to a full sternotomy. However, it has been demonstrated that TAVR is associated with increased perioperative complications, including: stroke or transient ischemic attack, incidence of vascular complications, permanent pacemaker implantation, and postoperative moderate and severe para-and transvalvular regurgitation (24) . No difference in all-cause mortality has been identified between SAVR and TAVR (9, 10, 24, 25) . MiniAVR is a second option for minimally invasive management of AS and has been shown to be equivalent to and possibly better than SAVR in terms of morbidity and mortality, while decreasing blood loss, ICU and hospital length of stays and recovery time (13, 19, (26) (27) (28) . The main drawback is the technical difficulty and prolonged AXC and CPB times. However, the utilization of sutureless valve implants has been shown to circumvent both of these pitfalls (21, 22, 26, 29, 30) . Although miniAVR is more invasive than TAVR, it retains the advantages inherent to SAVR. This includes the insertion of a durable prosthesis, rates of paravalvular leak of <1%, and comparable rates of perioperative myocardial infarction of 0.4% with miniAVR vs. 0.7% with SAVR (P=0.77) (19, 31) .
A paucity of data exist comparing TAVR and miniAVR. Direct studies are difficult as TAVR patients have typically been high-risk, while miniAVR patients tend to be lowrisk, as it is associated with longer AXC and CPB times. Even with propensity score analysis, it is difficult to make comparisons between the two techniques.
Both Miceli and Santarpino demonstrated a reduced survival rate and increased aortic regurgitation in the TAVR cohort (21, 22) . Terwelp demonstrated differences in postoperative rates of stroke and atrial fibrillation between TAVR and miniAVR. Therefore, it is important to consider the risk and impact of these complications on the individual patient when choosing between the two (23) . The fact that miniAVR has been shown to be equivalent to SAVR in terms of mortality, coupled with decreased blood loss, ventilator time, and ICU and hospital length of stay, may make miniAVR (especially with a sutureless valve) the ideal solution for managing high-risk patients who are not ideal SAVR candidates. However, it is most likely a first-line option for low-and intermediate-risk patients (26) .
Just as variable approaches exist for TAVR (transapical vs. transfemoral), miniAVR too can be performed via a number of incision pathways (ministernotomy, minithoracotomy, etc.). Miceli established a higher survival rate at 1 and 5 years and a lower incidence of postoperative atrial fibrillation, shorter ventilation time, decreased ICU and hospital length of stay in the minithoracotomy group as compared to the ministernotomy group (15) . These differences demonstrate the need for future studies to separate and distinguish the approaches, in order to more accurately measure and compare miniAVR outcomes.
Considering the current data and literature, we put forth the following opinion for AVR in patients with severe AS; it is clear that TAVR is an indispensable tool for treating severe AS in inoperable patients (8) . In high-risk patients, the data appears to support TAVR, and we believe this is an important therapeutic option. The data is less clear for intermediate-risk patients, but from the PARTNER 2A trial and a study by Reardon et al., comparing SAVR vs. TAVR in intermediate-risk patients, it appears that transfemoral TAVR is favorable (11, 32) . We believe it is important to recognize the potential caveats of these trials. Notably, the average age and STS PROM score for patients in PARTNER 2A were 81 years and 5.8%, respectively (11). Therefore, when evaluating patients for TAVR who are younger, or with a lower STS score, there needs to be recognition that these patients lie outside the demographic of the intermediate-risk trials. The PARTNER 2A study is also limited, in that patients were randomized to TAVR (transfemoral or transapical) or SAVR after being screened to see if the transfemoral approach would be feasible. This represents a selection bias by not randomizing treatment arms and selecting which patients will do better with the transfemoral approach. Another important consideration is that these trials never directly compared TAVR to miniAVR in intermediate-risk patients, and we believe that miniAVR may prove just as efficacious, if not superior.
Without a doubt, TAVR and miniAVR are here to stay. They have both proven to be essential tools that cardiac surgeons need to be comfortable using. With advances in technology and surgical technique, coupled with increased patient demand for minimally invasive procedures, increasing implementation is expected. Thus, it is imperative that more studies be conducted in order to accurately understand and appropriately apply TAVR and miniAVR. Currently, there is no risk-stratified trial directly comparing TAVR and miniAVR and neither technique should be discounted before such a trial is performed.
In conclusion, TAVR and miniAVR are burgeoning options but with little data to compare them. However, we believe there is a compelling role for miniAVR in low-and intermediate-risk patients. In the modern surgical era, even cardiothoracic surgery is beginning to experience the shift towards minimally invasive procedures. There needs to be © Annals of Cardiothoracic Surgery. All rights reserved.
Ann Cardiothorac Surg 2017;6(5):498-503 www.annalscts.com randomized, risk-stratified trials comparing TAVR and miniAVR before well-informed guidelines can be created. Either way, cardiac surgeons need to adopt these techniques as the data and outcomes clearly indicate their usefulness and necessity.
